The Durham University spin-out has secured funding from a number of sources
A North East tech company supporting new medicine discoveries has secured £1.3m to accelerate its work.
Magnitude Biosciences, a spinout from Durham University, has secured the funding to accelerate the commercialisation of VivoScan, which provides pharmaceutical and biotechnology companies with faster and more cost-effective ways to identify promising new treatments for ageing, longevity and neurodegenerative diseases.
VivoScan uses hundreds of nematode worms as a biological model to evaluate potential therapies. By combining the worms with advanced imaging, machine learning, agentic AI, automation and robotics, Magnitude Biosciences can generate whole-organism data in weeks rather than years.
The company’s work aims to offer faster alternatives to traditional drug testing models while supporting the growing industry shift towards research that is not performed on mammals.
Northstar Ventures has led the new round of investment into the company, committing capital from the North East Spinout Inspire Fund backed by the region’s five universities, as well as from the North East Innovation Fund and the Northstar EIS Growth Fund.
The funding will also mean that Magnitude Biosciences can access a £217,000 Innovate UK Investor Partnership grant.
Dr Fozia Saleem, CEO at Magnitude Biosciences, says: “Our ambition is to become the first company to provide a platform to screen millions of compounds in a whole organism. This investment in VivoScan gives us the opportunity to turn that ambition into reality and fundamentally change the scale and speed at which drug discovery can be done.
“We are building a platform that can move beyond simply screening more compounds. VivoScan generates rich, whole organism biological data that can help researchers understand how potential therapies affect health, ageing and disease. By making data generation faster and more cost effective, we will be able to help pharmaceutical and biotechnology companies identify better drug candidates earlier and ultimately accelerate the development of new treatments.”
The funding will be used to scale Magnitude Bioscience’s VivoScanTM platform, expand commercial activity with global pharmaceutical companies, invest in additional equipment and automation, as well as recruit new staff as the business enters the next stage of its evolution.
Dr Will Cousins, investment manager at Northstar Ventures, said: “The North East continues to generate world-class innovations with the potential to compete on the global stage. Supporting ambitious companies with the capital they need to grow is essential if we are to unlock that potential. Having worked closely with Magnitude Biosciences throughout its journey, we have seen first-hand the strength of the team, the technology and the opportunity ahead. We are proud to continue backing a business that is helping to shape the future of drug discovery.”
Sarah Newbould, Senior Investment Manager at the British Business Bank, said: “We’re continuing to back the businesses that are driving innovation across the UK economy, with this new funding round helping to bring Magnitude Biosciences’ new technology to market. With NPIF II providing initial investment in May last year, we’re able to support businesses throughout their journey, fuelling the Government’s Industrial Strategy and ensuring the North East’s life sciences sector continues to thrive.”




You must be logged in to post a comment Login